
AstraZeneca invests $1.5bn in Singapore facility for next-generation cancer drugs
The manufacturing facility, supported by Singapore's Economic Development Board, is for antibody drug conjugates, and will be designed to be "zero carbon" from its first day of operation in 2029.
May 21, 2024